Lisa Zimmer

9PUBLICATIONS
96CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsAllergyPredictive and prognostic markersAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 04, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

|Jul 27, 2025
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial.

Jürgen C Becker, Anja H Gesierich, Ulrike Leiter

|Jun 03, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma.

Georg C Lodde, Jessica C Hassel, Imke von Wasielewski

|Nov 27, 2024
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.

Giuseppe Tarantino, Cora A Ricker, Annette Wang

|Jan 31, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.

Catriona Harvey, Kazi J Nahar, Janet McKeown

|Sep 20, 2023
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.

Maximilian Haist, Henner Stege, Friederike Rogall

Pageof 2

Frequent Collaborators

5 joint publications

Bastian Schilling

5 joint publications

Dirk Schadendorf

4 joint publications

Elisabeth Livingstone

2 joint publications

Ralf Gutzmer